The importance of distinguishing atypical cytoplasmic indirect immunofluorescence patterns from the "classic", centrally accentuated cytoplasmic immunofluorescence pattern on ethanol fixed human neutrophils has recently been re-emphasised. [1] [2] [3] Autoantibodies to other cytoplasmic autoantigens such as antimitochondrial antibodies (AMA), antismooth muscle antibodies, and antiribosomal-P antibodies have also recently been reported to produce atypical cytoplasmic immunofluorescence patterns on ethanol fixed human neutrophils.
1 However, an alternative explanation is that the atypical cytoplasmic immunofluorescence patterns might be produced by concomitant antineutrophil cytoplasmic antibodies (ANCA) in these sera, especially in cases of autoimmune liver disease. Therefore, we investigated: (1) whether sera containing AMA with confirmed M2 specificity 4 produced positive indirect immunofluorescence patterns on ethanol fixed human neutrophils, and (2) the precise neutrophil antigen specificity of such sera.
Thirty two sera from diVerent patients with confirmed M2-AMA specificity (using the Inova Diagnostics (San Diego, California, USA) M2-AMA enzyme linked immunosorbent assay (ELISA)), were tested by indirect immunofluorescence on in house, ethanol fixed, normal human neutrophils and commercial HEp-2 cells (Sanofi Diagnostics Pasteur Chaska, Minnesota, USA). Twelve of the 32 patients had liver biopsies, which showed primary biliary cirrhosis in nine cases and autoimmune chronic active hepatitis in three.
All 32 sera were also tested on the ORGenTec (Mainz, Germany) Combi-kit® ELISA against the following neutrophil antigens: proteinase 3, myeloperoxidase, lactoferrin, elastase, cathepsin G, lysozyme, and bactericidal/permeability increasing protein (BPI). Table 1 gives the results. Thirteen of the 32 M2-AMA sera produced positive indirect immunofluorescent staining on the ethanol fixed neutrophils: ten had a perinuclear pattern (two of which might have been produced by concomitant ANA), and three had an atypical cytoplasmic pattern. The ORGenTec Combi-kit ELISA revealed that 22 (comprising all 13 sera that were immunofluorescence positive, and nine that were negative) of the 32 sera contained ANCA directed specifically against the following neutrophil antigens: BPI (n = 13), cathepsin G (n = 8), lactoferrin (n = 7), elastase (n = 2), proteinase 3 (n = 2), and lysozyme (n = 1). Five of these 22 sera contained ANCA against two neutrophil antigens, one against three neutrophil antigens, and one against five neutrophil antigens.
The immunofluorescence staining pattern did not appear to predict antigen specificity because the three atypical cytoplasmic immunofluorescence positive sera were associated with either anticathepsin G antibodies (n = 2) or anti-BPI antibodies (n = 1). Furthermore, the 10 perinuclear immunofluorescence positive sera were associated with either anti-BPI antibodies alone (n = 2), anticathepsin G antibodies alone (n = 1), antilactoferrin antibodies alone (n = 1), antilysozyme antibodies alone (n = 1), or a combination of two or more antibodies (n = 5). Finally, 10 of the 32 sera were negative for ANCA by both immunofluorescence and ELISA.
Therefore, we conclude that M2-AMA do not directly produce positive indirect immunofluorescence patterns on ethanol fixed human neutrophils. Rather, a positive indirect immunofluorescence pattern in M2-AMA positive sera appears to be produced by concomitant ANCA directed against a variety of neutrophil antigens such as BPI, cathepsin G, and lactoferrin. Further studies are necessary to determine whether autoantibodies to other cytoplasmic autoantigens directly produce positive immunofluorescence patterns on ethanol fixed human neutrophils, 1 or whether these sera contain concomitant ANCA. 
Raised plasma parathyroid hormone related peptide in gastric adenocarcinoma
We report a case of humoral hypercalcemia associated with a rapidly growing gastric carcinoma. To our knowledge, this is the first such case of gastric carcinoma reported with raised plasma parathyroid hormone related peptide (PTHrP) and absent bone metastases. A 69 year old woman presented with fatigue and intermittent sharp epigastric pain for one week. Upper gastrointestinal radiographs and endoscopy demonstrated a necrotic, friable mass in the mid stomach. Biopsy of the mass and a surrounding satellite ; Fe, < 2 µmol/litre; and total iron binding capacity, < 21 µmol/litre. Chest x ray was negative. Two weeks later the patient developed mental confusion and dehydration. Serum calcium was 2.8 mmol/litre, phosphorus 0.5 mmol/litre, and albumin 26 g/litre. With intravenous hydration and pamidronate (90 mg), serum calcium rapidly became normal and the patient's mental status returned to baseline. Neither radionuclide bone scan nor magnetic resonance scan of the brain suggested metastases. The intact PTH (IRMA; Nichol's Institute) was 6 ng/litre (normal, 10-65). However, PTHrP (1-40 IRMA; Nichols Institute) was 5.4 pmol/litre (normal < 1.3). The patient died of progressive liver failure three weeks later.
Hypercalcaemia is rarely associated with gastric cancer. In the literature, two cases of gastric adenocarcinoma with hypercalcaemia have been reported in which the tumour cells expressed PTHrP. ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotising vasculitis Dr Harris's results 1 showed that indirect immunofluorescence is a more sensitive technique than antigen specific enzyme linked immunosorbent assay (ELISA) for the diagnosis of systemic necrotising vasculitis (70% v 50%) but that ELISAs have a higher positive predictive value (87% v 76%). It was the greater sensitivity of indirect immunofluorescence that prompted the "International consensus statement on testing and reporting antineutrophil cytoplasmic antibodies (ANCA)" 2 to require all laboratories to screen for ANCA by indirect immunofluorescence, but to confirm the specificity of fluorescent sera by ELISA. In our hands, adherence to the minimum requirements of the consensus statement results in a higher positive predictive value than either indirect immunofluorescence or ELISA alone (62% compared with 44% and 50%, respectively). Screening by indirect immunofluorescence has the additional advantages of being a quicker and cheaper technique than using the two commercial antigen specific ELISAs that are usually required and, furthermore, indirect immunofluorescence might demonstrate coincidental but unsuspected autoantibodies such as antinuclear antibodies. We believe that the use of ELISAs alone to diagnose a systemic necrotising vasculitis is analogous to testing for systemic lupus erythematosis with anti-double stranded DNA antibodies rather than initially screening for antinuclear antibodies by indirect immunofluorescence. The authors reply Our study was carried out following the preliminary observation that in our laboratory a positive immunofluorescence antineutrophil cytoplasmic antibody (ANCA) result was less frequently associated with a diagnosis of systemic necrotising vasculitis than a positive enzyme linked immunosorbent assay result (PR3 or myeloperoxidase). Our clinicians frequently did not alter management based on the immunofluorescence ANCA result. In fact, our renal physicians invariably proceeded with renal biopsy, regardless of immunofluorescence results, to confirm or refute the diagnosis of systemic necrotising vasculitis. The ELISA result frequently came back too late to alter clinical management, the ELISA test being done when immunofluorescence was positive. Our study has shown that for active systemic necrotising vasculitis, ELISA has a superior positive predictive value and specificity, and comparable sensitivity to the immunofluorescence technique. Savige et al quoted our sensitivity results with respect to "all cases" of systemic necrotising vasculitis, active and inactive combined, which are largely irrelevant parameters in clinical practice because the need is to identify active cases. The principal result of the study was the finding that in active, biopsy confirmed cases of systemic necrotising vasculitis, ELISA ANCA is just as sensitive (85% v 88%; p = 0.056) yet has a signifi- cantly better specificity (97% v 90%; p = 0.0006) and positive predictive value (73% v 50%; p = 0.0013) compared with immunofluorescence ANCA.
The fact that the sensitivity of ELISA ANCA falls as inactive cases are added to active cases implies that ELISA more quickly becomes negative as active disease settles, whereas immunofluorescence remains positive. This observation suggests that ELISA is also a better test in following disease activity after diagnosis and initiation of treatment.
Savige et al reported their finding of a higher positive predictive value if results of ELISA and immunofluorescence ANCA are combined. This was not found in our study. In fact, combining immunofluorescence and ELISA ANCA resulted in a lower positive predictive value than ELISA ANCA alone. It would be of interest to review the data Savige et al have used.
Based on our results, we conclude that ELISA ANCA is the principal serological test for the diagnosis of systemic necrotising vasculitis. Immunofluorescence ANCA should be avoided because its inferior specificity and poor positive predictive value open the way to incorrect or delayed diagnosis and treatment. We would like to restate the importance of recognising the diVerent clinical syndromes caused by systemic necrotising vasculitis and of appropriate histological testing even with a positive or negative ELISA ANCA result.
We have not investigated the value of ANCA with respect to the diagnosis of other conditions, such as inflammatory bowel disease, and so we do not recommend which tests should be used in a particular laboratory. We have only compared ELISA and immunofluorescence ANCA in a particular disease (systemic necrotising vasculitis) and found ELISA to be superior by all criteria. Our results indicate that the "International consensus statement on the testing and reporting of ANCA" 1 should be revisited. 
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The eVect of using templates on the information included in histology reports on specimens of uterine cervix taken by loop excision of transformation zone (LETZ)
I should again like to congratulate Dr Al-Nafussi and her colleagues for providing us with an interesting and stimulating paper 1 and to take the opportunity to add some comments of my own. Following earlier correspondence in the journal, 2 3 I have sought to develop a system of standardised phrases that are used in reporting the features listed in the paper by Reid et al.
1 Secretarial or medical staV can enter a short code of up to 35 letters, which is expanded electronically to produce a phrase or sentence in coherent English. In this department, we use the Telepath system, which allows more than one such code to be used in any given report. Snomed codes are linked to the codes and automatically included in the departmental database. Furthermore, it is possible to recover reports in which a given standardised phrase or sentence has been used. This allows us to identify the proportion of cases with specific findings such as involved specimen edges, traumatised squamocolumnar junctions, or the presence of endocervical epithelium or squamous epithelium at the end of the endocervical canal. Because these are quality features that are to some extent under the control of the colposcopist or surgeon, it is envisaged that we can then provide feedback on the adequacy of specimens deriving from particular clinics to the responsible consultants.
Finally, in addition to the ectocervical and endocervical edges we routinely comment upon the presence of CIN (cervical intraepithelial abnormality) at the deep lateral edge. This is the edge that runs between the superior, endocervical edge of the specimen to the lateral, ectocervical edge of the specimen. Although this is composed of cervical stroma with variable degrees of cautery artefact, we regard this involvement as being important because there is the potential of residual disease being covered in the reepithelialisation process, so that it will not be detected on colposcopy or cytological surveillance. Residual disease, if undetected, has been suggested as a cause of later invasive cervical carcinoma in patients treated for CIN. 
Some problems found in HIV-1 RNA quantification
The polymerase chain reaction (PCR) based assay of human immunodeficiency virus type 1 (HIV-1) RNA in plasma is now commercially available and is used widely for the assessment of antiretroviral treatments. The kit is called the Amplicor TM HIV-1 monitor test kit version 1.0 from Roche Diagnostics (Tokyo, Japan). However, this system is not sensitive enough for the accurate measurement of genetic subtypes A and E, and it gives falsely low titres for these virus subtypes.
1 2 To surmount this problem, additional gag primers (AG primers) have been provided by Roche for research use (Ver. 1.0 plus). Furthermore, a new improved version (Ver. 1.5) was developed recently, which is said to yield accurate results not only on subtype B but on subtypes A and E. With the Ver. 1.0 plus kit, adding the AG primer set from the Ver. 1.5 kit to the PCR master mixture containing the Ver. 1.0 primer set makes it possible to amplify even subtype A and E viruses. In the Ver. 1.5 kit, the downstream primer is 12 bases downstream from the Ver. 1.0 primer position, whereas the upstream primer position is unchanged but the primer has two base substitutions. In our laboratory, we have examined over 1500 samples (148 cases) using the Ver. 1.0 kit, and among them, 150 samples (65 cases) were also measured with the Ver. 1.0 plus kit. As expected, most cases with the HIV-1 subtypes A and E, which could not be measured with the Ver. 1.0 kit, could be measured with the Ver. 1.0 plus kit. However, we were particularly interested in a few cases that gave unexpected results. Clinically and epidemiologically, these patients are not diVerent from our other patients infected with HIV-1 subtypes A or E. As shown in table 1, case 1 gave equivalent results with all of the kits but in cases 2 to 5 higher results were obtained with the Ver. 1.0 plus kit than with the Ver. 1.0 kit. We measured these specimens with the Ver. 1.5 kit (kindly provided by Roche Diagnostics, Japan). In these five cases, all but case 2 revealed equivalent values with both the Ver. 1.0 plus and Ver. 1.5 kits. Unexpectedly, in case 2, only the Ver. 1.0 plus kit yielded the accurate results.
On the other hand, in case 6, a higher result was obtained with the Ver. 1.0 kit but not with the Ver. 1.0 plus or Ver. 1.5 kits. An additional two cases showed a similar trend, although the degree of discrepancy was less severe (data not shown). Case 1 Test results of each case are summarised. Measurements with Amplicor HIV-1 monitor test kits Ver. 1.0, 1.0 plus, and 1.5 were performed according to the manufacturer's protocol. The per cent coeYcient of variation on the same samples tested with the Amplicor HIV-1 monitor test kits Ver. 1.0 and 1.0 plus in our laboratory were 19.9% (n = 17) and 31.9% (n = 12), respectively. In cases 2 and 6 the viral load was confirmed with another independent measurement (second result). To clarify the cause of these discrepant results, sequence analysis of the amplified regions of these cases was performed. The nucleotide sequences of these cases were found to be homologous to subtype A or E virus when they were aligned with the consensus sequences of HIV-1 subtypes A, B, and E obtained from the HIV Sequence Database WWW home page (Sequences. (Online.) http://hiv-web.lbnl.gov. 30 October 1999, last date accessed.) . Surprisingly, the sequences of the primer regions of all cases were completely identical (fig 1) . In conclusion, cases 2 and 6 are measurable by one of these kits, Ver. 1.0 plus and Ver. 1.0, respectively; and case 1 is measurable by all kits despite having the same nucleotide sequence in the primer regions as the other cases. The results of sequence analysis of the primer regions suggests that the minor diVerences in sequence between the virus and the primers does not always aVect amplification eYciency in these kits. Although such cases might form a minor population among HIV-1 infections, these results indicate that some cases could not be measured by a single kit. As far as we have experienced, even if one kit fails to measure virus, the other will yield the expected viral load, as judged by disease history, CD4 count, treatment, and so on, suggesting that these kits are mutually complementary. If other methods, such as nucleic acid sequence based amplification or branched DNA (bDNA) systems, are available, it would be useful to test with them. We have found some cases of subtype A or E that have shown a higher viral load with bDNA (Chiron Quantiplex TM HIV RNA 2.0 assay Chiron Corporation, Emeryville, California, USA) than the Amplicor HIV-1 monitor test kit (data not shown). In patients infected with subtype B virus, the correlation between the Amplicor HIV-1 monitor test kit and the bDNA method was excellent (r = 0.904; n = 21). In conclusion, because the major diVerence in the three versions of the Amplicor HIV-1 monitor test kit is the primer set, we emphasise that for accurate quantitative measurement using this kit various additional primer sets that can amplify similar regions are needed.
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Next of kin clinics
We read with interest the considered views of Professor Vanezis and Dr Leadbeatter regarding the role of forensic pathologists dealing with the next of kin of those people whose deaths are subject to medicolegal investigation. 1 It might be of interest to your readers to know that the issues raised by the authors have been dealt with at the department of forensic medicine, at Westmead in Sydney for the past decade.
The department oVers a specialist grief counselling service, targeting the needs of families attempting to come to terms with the complications of a coronial investigation at a time of crisis and great distress. The counsellors routinely contact the next of kin in all cases, discussing with them forensic and coronial procedures and outlining the counselling service, which includes individual sessions, group debriefing, and court support. The service operates with the full support of the New South Wales State Coroner, but is funded solely by the department of forensic medicine.
Professor Vanezis and Dr Leadbeatter propose the provision of "next of kin clinics", conducted by the pathologist, to discuss postmortem findings. Such a service is regularly provided at Westmead as part of the counselling unit's brief. Although thoroughly endorsing the authors' remarks on the need for accurate and timely information, we have found that several alterations need to be made to the model broadly outlined by the authors for the families to gain maximum benefit from the information sessions.
These include: + Ongoing contact between the family and the counsellor from the time of necropsy to the receipt of its results, to ensure that the family is confident that forensic staV will be both frank and reliable in the delivery of information and support. + A preliminary session between the family and the counsellor, to ensure that all the family's concerns are identified, thereby ensuring that the meeting with the pathologist is as comprehensive as possible. + The presence of the counsellor at the meeting as mediator and support person for the family. Such a mediation role involves ensuring that all the family's issues are adequately considered, that the tendency some pathologists have to use jargon is kept under control, and that clarification is sought where necessary. We have found that these alterations are necessary to ensure that the emotional needs of the family and the occasionally unavoidable power imbalance between grieving relatives and a medical specialist are properly dealt with. This latter concern can most clearly be seen in the reluctance of non-medically trained relatives to seek clarification and to admit to doubts and concerns while speaking with a representative of "the system", however well intentioned.
We have been pleased with the success of the service over many years, and self reported feedback from clients suggests both a sense of confidence in the forensic system and in coronial findings as a result. We are delighted that our colleagues in the Northern Hemisphere are finally becoming aware of the value of such a system. The authors reply Drs Drayton et al are to be congratulated on setting up what appears to be a splendid service for relatives, and we note with interest their comments, particularly on how we could modify our work practice in the UK. We have always been conscious of the fact that when running such clinics we have had to tread very carefully, bearing in mind the sensitivities of relatives, as well as our medicolegal obligations to the investigating authorities. The system we have adopted is designed to provide information to the next of kin regarding the necropsy performed on their loved one, and to answer any concerns they might have regarding our findings. It is not designed to be a specialist grief counselling service. We have intentionally not attempted to take this approach because as pathologists we are not grief counsellors. Nevertheless, it would be extremely useful for all doctors to have some formal training in dealing with the bereaved. As you can appreciate, we have given some thought to the structure we have adopted, and what our role would be in such clinics in relation to our own situation in the west of Scotland, and obviously we would like to see the service that we provide extended to other areas in the UK. As we have stated in our paper, the service we oVer at the present time, albeit limited when compared with the one oVered in Australia, is nevertheless very welcome and we believe of some benefit to the next of kin.
Because of an error in the publishing process, the wrong figure was published as fig 6 in this paper. The following figure is the correct one. The journal apologises for this error. 
